In vivo, corilagin significantly reduces xenograft tumor growth and uniquely blocks TGF-β secretion and Snail stabilization, effectively inhibiting both canonical Smad and non-canonical ERK/AKT pathways [187]. This evidence concerns the gene AKT1 and neoplasm.